Reata Pharmaceuticals - CARDINAL Study for Alport Syndrome
Reata Pharmaceuticals - CARDINAL Study for Alport Syndrome

Details

Location

Description

A clinical trial designed specifically for patients with Alport syndrome.

CARDINAL is a Phase 2/3 clinical study evaluating the safety and effectiveness of bardoxolone methyl (an oral investigational drug) for the treatment of Alport syndrome. Up to 210 participants will be enrolled in CARDINAL at approximately 60 research centers around the world.

 

Visit https://www.cardinalclinicaltrial.com/ to learn more.